Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions

This article was originally published in The Pink Sheet Daily

Executive Summary

Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.


Related Content

Creating Value In Pharma-Health Plan Collaborations
Germany’s Pricing Revolution: Why The World Should Be Watching
AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus
Pharma/Payer Deals: 2011 Saw Important Step In Shift To Value-based R&D
The Year Ahead In Europe: More Price Cuts, More Austerity
Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe
AZ’s Brilinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward
U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy
AstraZeneca, HealthCore Launch Outcomes Data Project, Seek Multi-Stakeholder Consortium


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts